BM BMY Bristol Myers Squibb Loading... : Bullish and Bearish Analyst Opinions

Bristol-Myers Squibb reports that its drug Izalontamab Brengitecan shows significant overall survival and progression-free survival improvements in TNBC and ESCC.

SEC FOIA logs reveal ongoing investigations for listed companies, indicating regulatory scrutiny but no directional view expressed.

Bristol-Myers Squibb and China's Hengrui Pharma announced a partnership, but the tweet reports the deal without expressing a forward-looking opinion on the stock.

BP is reportedly exploring potential M&A opportunities involving Novartis's oncology unit and Bristol Myers Squibb's neurology division.

BMY faces the steepest patent cliff with 47% of its revenue at risk and carries a high debt load from aggressive M&A. Despite a cheap valuation, the combination of massive revenue exposure and high debt restricts their flexibility, making them a high-risk investment. Avoid BMY as it is currently a "value trap." Recent M&A acquisitions could yield blockbuster results faster than anticipated, offsetting the cliff.

Cramer agreed with Bob Lang's analysis that it's time to buy big pharma names like Pfizer, Merck, and Bristol Myers for their dividends and safety in a potential slowdown. These companies have strong dividend yields (e.g., Pfizer 6.3%, Merck nearly 3%, Bristol Myers 4.3%), bullish technical indicators (money flow, cup-and-handle patterns), and are recession-resistant as medication demand is inelastic. LONG because they offer yield protection and potential capital appreciation in a potential economic slowdown, making them defensive plays. If the economy avoids a slowdown, these stocks might underperform growth sectors; drug pipeline setbacks could impact earnings.